M. R. Blum

Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus

J. Bartlett, S. Weller, H. Gallis, 1989, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy

S. Weller, M. Smiley, M. Schultz, 1996, Antimicrobial agents and chemotherapy.

Single-dose pharmacokinetics of acyclovir

S. Spector, J. Connor, R. Keeney, 1981, Antimicrobial Agents and Chemotherapy.

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. Jacobson, S. Weller, J. Gallant, 1994, Antimicrobial Agents and Chemotherapy.

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.

W. Parks, S. Weller, Y. Bryson, 1993, American journal of obstetrics and gynecology.

Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults

J. Bartlett, J. Mellors, S. Riddler, 1996, Antimicrobial agents and chemotherapy.

Pharmacokinetics of acyclovir suspension in infants and children

M. Levin, J. Connor, S. Weller, 1987, Antimicrobial Agents and Chemotherapy.

Acyclovir kinetics after intravenous infusion

D. A. Page, D. Cocchetto, G. Hemstreet, 1979, Clinical pharmacology and therapeutics.